CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hi, good morning and good evening, everyone. Can you hear me? Yes, yes, Yifeng can. Yeah, sorry, we have some technical issue just now. So I would like to thank you for your time to join our earnings call today. Yeah, this is Yvonne, the CFO of Apostatomed Therapeutics. And I have my team with me. So I would like to proceed with our presentation. Yeah. Before kick-off of my presentation, please note that we will be making forward-looking statements today, which may differ materially from actual results. Please review our legal disclaimer included in all our presentations carefully. I will now give you a broad overview of the 6-month ended 30 June 2025 financial performance. Our revenue increased by 100% to $156,000 for the 6 months ended 30 June 2025. Other operating income decreased by 8.5% year-on-year. We reported a net loss of $2.25 million in 2025. Our net loss will be reduced to $1.44 million if the share-based payment, net currency exchange losses, the fair value losses on Warren Liability and the costs associated with being a publicly listed company are excluded. Loss per share was $0.19 for 6 months ended 30 June 2025. As at 30th June 2025, we have cash and bank balances of $2.86 million. Our MTS stood at $7.15 million. We move on to the next slide. The table shows the financial performance for the 6 months ended 30th June 2024 and 2025. In first half of 2025, we started generating revenue of $156,000 from private blood banking services after acquiring the license and certain assets under IPSC depository. This is one of our subsidiary in Malaysia. Other operating income decreased by 8.5%. from $422,000 in first half 2024 to $336,000 in first half 2025. This decrease was mainly driven by a reduction of $105,000 in interest income from the placement of IPO pro...